Axelar and Cadila Pharmaceuticals announce co-development agreement for Non-Small Cell Lung Cancer Treatment

Dokument -

Axelar and Cadila Pharmaceuticals announce co-development agreement for Non-Small Cell Lung Cancer Treatment

Axelar AB and Cadila Pharmaceuticals Sweden AB have entered into a co-development agreement for further formulation development and clinical development of AXL1717 in patients with non-small cell lung cancer. Cadila Pharma will co-invest a proportion of the projected costs for formulation development and clinical trials and will in return receive geographic market rights and revenue sharing.
Licens:
All rights reserved
Innehållet får bara användas av Mynewsdesk. Det är alltså inte tillåtet för någon annan att ladda ner, kopiera, sprida eller på annat sätt använda Innehållet (annat än för privat bruk i den mån det följer av lag).
Filformat:
.pdf

Relaterat innehåll

Axelar and Cadila Pharmaceuticals announce co-development agreement for Non-Small Cell Lung Cancer Treatment

Axelar AB and Cadila Pharmaceuticals Sweden AB have entered into a co-development agreement for further formulation development and clinical development of AXL1717 in patients with non-small cell lung cancer. Cadila Pharma will co-invest a proportion of the projected costs for formulation development and clinical trials and will in return receive geographic market rights and revenue sharing.